{
    "2021-02-01": [
        [
            {
                "time": "",
                "original_text": "中泰证券---贝达药业：业绩表现亮眼，创新管线不断丰富【公司研究】",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "业绩表现",
                        "创新管线",
                        "丰富"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：争做国产创新药研发的标杆企业",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "国产创新药",
                        "标杆企业"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558)：恩沙替尼与埃克替尼研究数据亮眼 Q4超预期",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "恩沙替尼",
                        "埃克替尼",
                        "研究数据",
                        "Q4",
                        "超预期"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558)：业绩表现亮眼 创新管线不断丰富",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "业绩表现",
                        "创新管线",
                        "丰富"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国金证券---贝达药业：公司业绩稳步增长，恩莎替尼一线数据更新【公司研究】",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "业绩增长",
                        "恩莎替尼",
                        "一线数据",
                        "更新"
                    ],
                    "sentiment_score": 0.88,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}